• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

    2/19/25 9:01:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLUR alert in real time by email

    KEMPTTHAL, Switzerland and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Foodtech innovator Ever After Foods (EAF) and global food leader Bühler today announced an expansive cultivated meat collaboration to help food producers around the globe produce cultivated meat efficiently at mass scale. Bühler and Ever After Foods will work together to bring a commercial-scale cultivated meat production system, which allows commercial production at ten-fold lower scale than existing technologies, to market.

    Bühler aims to foster the development of equipment to enable market-ready, sustainable, healthy, and affordable cellular products that can address increasingly complex food system challenges, reduce environmental impact and improve food security. Ever After Foods provides the technology to deliver commercial-scale production systems specifically designed to meet the needs of the cultivated meat sector.

    "The global food chain faces significant challenges if we are to successfully and sustainably feed our growing population. How we produce and consume protein will continue to change, and requires a transition of our protein system to deliver this. Powering cultivated meat production at scale with a patented production system, Ever After Foods will help the food industry keep pace with the protein demands of a growing global population," noted Ian Roberts, CTO at Bühler.

    Dedicated to leading a new era of scalability and sustainability for cultivated meat, Ever After Foods is working closely with select cultivated meat companies and top leaders in the food industry to accelerate the development and global deployment of its proprietary edible packed-bed (EPB™) technology platform. Ever After Foods is actively creating scalable production solutions for clients, and its collaboration with Bühler will pave the way for dedicated and continued support of production solutions in the sector.

    "The cultivated meat industry must move beyond relying on pharma-based technologies and adopt solutions specifically designed for food production," said Eyal Rosenthal, CEO of Ever After Foods. "Our strategic collaboration with Bühler, a global leader in food equipment, is a critical step toward delivering scalable and efficient technologies that empower cultivated meat producers and food companies to bring their products to market. Together, we are driving the development of tailored solutions to sustainably scale cultivated meat production."

    With Ever After Foods, cultivated meat producers can reduce production costs by over 90% while achieving unparalleled production efficiency. Alongside these advancements, Ever After Foods' platform offers key biological advantages, including enhanced nutritional value and superior flavor.

    The company has successfully demonstrated its technology in collaboration with industry partners enabling the natural production of both muscle and fat tissues for beef, chicken, duck, and fish cells. This ensures an exceptional replication of conventional animal-derived meat in taste, texture, and overall experience. Ever After Foods provides the cutting-edge production platform partners need to scale and achieve high-yield cultivated meat production.

    About Bühler

    Bühler holds a leading position in the global food and feed industry, contributing to feeding over 2 billion people every day. Bühler brings expertise in processing technologies, a deep knowledge of the cost competitive food and feed markets, and global access to those markets. Bühler is supporting new applications and technology developments in these fields, that would allow to considerably reduce the environmental footprint of the food and feed industry.

    About Ever After Foods

    Ever After Foods is transforming cultivated meat production with its proprietary technology platform, designed to create scalable and cost-efficient production systems. By producing slaughter-free, ethical, and delicious premium meat products, Ever After Foods is paving the way for a sustainable future. Committed to bringing cultivated meat to the mass market, the company is redefining how cultivated meat is produced at scale.

    Learn more at https://everafterfoods.com/.

    Contact:

    Erica M. Camilo

    (610) 639-5644

    [email protected] 



    Primary Logo

    Get the next $PLUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLUR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    1/5/26 7:43:14 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manieu Alexandre Weinstein was granted 519 shares, increasing direct ownership by 5% to 10,769 units (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    12/8/25 4:07:47 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ajchenbaum Eitan was granted 668 shares, increasing direct ownership by 6% to 12,353 units (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    12/8/25 4:07:04 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manieu Alexandre Weinstein was granted 10,250 shares, exercised 1,002,169 shares at a strike of $0.00 and bought $2,086,956 worth of shares (452,702 units at $4.61) (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    11/20/25 11:35:50 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    7/1/25 4:00:11 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent

    Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China's growing cell therapy market and supports cross-border partnerships  HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we", "our" or "us") (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces that the China National Intellectual Property Administration (CNIPA) has gra

    2/18/26 8:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials

    HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the first phase of its program with Resbiomed Technologies OOD ("Resbiomed"), a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri's contract development and manufacturing division, PluriCDMO™. In June 2025, Pluri Biotech Ltd., a wholly owned subsidiary of the Company, and a provider of Contrac

    1/22/26 9:15:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

    HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. ("Remedy Cell"), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. Under the ongoing collaboration Remedy Cell's personnel, along with Pluri's Contract Development and Manufacturing Organization ("CDMO") division (PluriCDMO™), have successfully completed the full imp

    12/22/25 7:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    SEC Filings

    View All

    Pluri Inc. filed SEC Form 8-K: Other Events

    8-K - Pluri Inc. (0001158780) (Filer)

    3/2/26 9:00:21 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Pluri Inc.

    10-Q - Pluri Inc. (0001158780) (Filer)

    2/12/26 4:01:55 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Pluri Inc. (0001158780) (Filer)

    1/22/26 4:05:39 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Financials

    Live finance-specific insights

    View All

    BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

    Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

    11/11/24 6:00:00 AM ET
    $BCLI
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Leadership Updates

    Live Leadership Updates

    View All

    Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

    HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

    3/6/24 7:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

    HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

    7/13/23 2:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    2/13/24 4:34:49 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    2/1/24 4:02:29 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    9/15/23 4:00:03 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care